Navigation Links
Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program
Date:1/20/2009

SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced that it will focus resources on the development of its natriuretic peptide franchise, including CD-NP which is in Phase II development for acute heart failure, and CU-NP which is a pre-clinical compound. Nile will suspend the further development of 2NTX-99 and return license rights for the compound to Dr. Cesare Casagrande.

"We are disappointed that we are unable to continue to pursue the development of 2NTX-99," stated Peter Strumph, Chief Executive Officer of Nile. "We have decided to terminate this program in order to focus our resources on our core natriuretic peptide program, which is showing great promise as a potential treatment for cardiovascular and renal disease."

Results from two completed Phase I studies and the ongoing open-label Phase IIa study support advancing the CD-NP development program into a Phase IIb clinical study. Current development plans include initiating a 30 patient placebo-controlled clinical study of acute heart failure patients with renal impairment. This study is designed to assess safety and efficacy of early administration of CD-NP in this patient population and may provide additional evidence to support the hypothesis that CD-NP enhances renal function. Such results would build upon the recently completed Phase Ib study in which CD-NP demonstrated diuretic effects comparable to furosemide and produced statistically significant changes on biomarkers consistent with enhanced renal function.

"Another study showing that CD-NP enhances renal function will go a long way towards establishing that CD-NP has differentiated and favorable renal properties relative to current and development treatments for acute heart failure," commented Peter Strumph. "In addition, this study, which ca
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
2. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
3. Dr Stephan Rietiker Joins BioCeramic Therapeutics
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
6. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
7. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
8. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
9. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
10. Horizon Therapeutics Announces Senior Management Appointments
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from ... first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members ... course combines students from both universities and is taught on both continents. , ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
(Date:6/30/2015)... ... 30, 2015 , ... uBiome and OpenBiome Partner for Microbiome ... fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and OpenBiome ... microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). , ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares ... outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, the ... price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... CHAPEL HILL, N.C., Oct. 20 With ... expenditures toward support of Continuing,Medical Education activities, ... anxious to understand the value of CME,support ... impact,on healthcare practitioner behaviors and patient outcomes. ...
... directors,of Eli Lilly and Company (NYSE: LLY ) today ... a share on outstanding common stock. This,is the same dividend ... and,brings the total annual dividend for 2008 to $1.88 per ... shareholders of record at,the close of business on November 14, ...
... The Board of Directors,of Eli Lilly and Company (NYSE: ... a,new member, effective December 1, 2008. Oberhelman, 55, currently ... a member of Caterpillar,s,executive office. As a member of ... committee and finance committee. He will stand for,election by ...
Cached Biology Technology:Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME) 2Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... 2013 Elsevier, a world-leading provider of scientific, technical ... announce the launch of a new journal: Methods ... and adding to Elsevier,s Aquatic Sciences portfolio of journals, ... focus on new methodology of oceanographic research. ...
...  The governments of Southeast Asia (SEA) ... (ANZ) are investing heavily in security projects and infrastructure, ... bodes well for the biometrics market in the two regions. ... countries to implement biometric passports by 2015 is further accelerating ...
... associated with disorders like diabetes, Harvard researchers have shown ... plays another critical role in the body helping ... to showing that the insulin-like peptides play a critical ... learning and memory, a team of researchers led by ...
Cached Biology News:Government Emerges As the Biggest Spender on Biometrics in the SEA and ANZ Markets, Finds Frost & Sullivan 2Government Emerges As the Biggest Spender on Biometrics in the SEA and ANZ Markets, Finds Frost & Sullivan 3Government Emerges As the Biggest Spender on Biometrics in the SEA and ANZ Markets, Finds Frost & Sullivan 4Linking insulin to learning 2